Max Healthcare Q4 FY26 Revenue Rises 10% YoY to ₹2,664 Crore; EBITDA at ₹682 Crore, PAT at ₹387 Crore

Key Metrics:

What Happened ?

Key Details

Q4 FY26 Operational and Strategic Developments:

• Gross revenue increased 10% YoY to ₹2,664 crore driven primarily by higher occupied bed days and sustained demand across the hospital network.
• International patient revenue rose 12% YoY to ₹227 crore and contributed nearly 9% of hospital revenues.
• Network operating EBITDA increased 8% YoY to ₹682 crore while operating margin remained healthy at 26.8%.
• Clinician costs increased materially due to aggressive hiring of medical talent to support future capacity additions and hospital expansions.
• Max Lab revenue grew 14% YoY to ₹52 crore with operations now spanning 60+ cities and over 2,700 diagnostic tests.
• Max@Home revenue rose 30% YoY to ₹73 crore supported by rehabilitation services, nursing care, medicine delivery, and diagnostics at home.
• Free treatment worth approximately ₹59 crore was provided to economically weaker patients during Q4 FY26.
• The company operationalized approximately 20% additional brownfield capacity over the last six months with another ~10% expected through the Gurugram facility later this year.
• The 400-bed Max Smart expansion became operational in April 2026 with 156 beds already handed over for operations.
• Mohali’s 160-bed brownfield tower has been fully commissioned and operationalized.
• Nanavati-Max operationalized 116 beds out of planned 280 beds, with remaining beds expected in the next three months.
• Max Healthcare completed acquisition of a 58.28% stake in Kalinga Hospital Ltd., making it a subsidiary effective May 18, 2026.
• Kalinga Hospital operates a 250-bed hospital on a 10-acre land parcel in Bhubaneswar, Odisha.
• The board approved investment of approximately ₹1,400 crore for a new 712-bed Lucknow greenfield hospital expected to be commissioned in FY30.
• The company also executed a share purchase agreement for staggered acquisition of Yerawada Properties Pvt. Ltd. to develop a ~450-bed hospital in Western India.
• The board approved brownfield expansion at MSSH Dwarka adding 260 additional beds.
• The board recommended a dividend of ₹2 per share for FY26 subject to shareholder approval.

Note:

• The company indicated that ongoing brownfield expansions and newly operationalized capacities are expected to generate operating leverage as occupancy ramps up over coming quarters.  

Risk Analysis

Summary:

• Despite strong operational performance, margin pressures remain due to higher clinician hiring costs, expansion-related expenses, and changing oncology drug procurement dynamics.

Key Risks:

• EBITDA margin moderated to 26.8% from 27.2% YoY.
• Clinician costs increased significantly due to advance hiring for future capacity additions.
• Oncology revenue mix declined due to discontinuation of select chemotherapy drugs for institutional patients.
• Large-scale expansion projects may temporarily impact return ratios and operational efficiency during ramp-up phase.
• Net debt increased versus FY25 levels due to expansion investments and acquisitions.
• Ongoing integration risk exists for Kalinga Hospital acquisition.
• Significant capex commitments for Lucknow, Gurugram, and future projects may elevate leverage temporarily.

Worst Case Scenario:

• If occupancy ramp-up in newly commissioned hospitals is slower than expected or clinician cost inflation continues, operating margins and return ratios could remain under pressure while debt levels rise due to expansion capex.

Company Commentary